Lawrence Byrd, MD
Nephrology · Livingston, NJNPI 1619916756
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $272,746 of the $337,866 with a category attached, or 80.7%. Bayer accounts for 87.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $114,839 and has fallen 73.4% since, to $30,597 in 2025. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 365 payments — averaging $925.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$294K
- Vifor Pharma, Inc.$41K
- AstraZeneca$1K
- GSK$185
- Amgen$146
- Arbor Pharmaceuticals, Inc.$120
- plus $534 from 14 others
What the payments were for
- Consulting fees$5,0842%
- Speaking & faculty fees$272,74681%
- Travel & lodging$51,36215%
- Food & beverage$8,4833%
- Education$1910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 226 | $294,218 |
| Vifor Pharma, Inc. | 62 | $41,304 |
| AstraZeneca(2 entities) | 17 | $1,359 |
| GSK | 1 | $185 |
| Amgen(2 entities) | 10 | $146 |
| Arbor Pharmaceuticals, Inc. | 12 | $120 |
| Travere Therapeutics, Inc. | 6 | $96 |
| OPKO Pharmaceuticals, LLC | 6 | $85 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Fresenius USA Marketing, Inc. | 3 | $43 |
| Ultragenyx Pharmaceutical Inc. | 3 | $42 |
| Genentech USA, Inc. | 3 | $41 |
| Daiichi Sankyo Inc. | 3 | $40 |
| Shire North American Group Inc | 3 | $36 |
| Calliditas Therapeutics US Inc. | 1 | $27 |
| Akebia Therapeutics Inc | 2 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$337,866 in reported general payments places this provider in the 95th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 213 | $170,844 |
| Phenoxybenzamine Hcl | 11 | $142,411 |
| FarxigaDapagliflozin Propanediol | 95 | $96,587 |
| VeltassaPatiromer Calcium Sorbitex | 58 | $48,874 |
| LokelmaSodium Zirconium Cyclosilicate | 34 | $27,390 |
| ProcritEpoetin Alfa | 11 | $19,437 |
| EdarbiAzilsartan Medoxomil | 33 | $14,566 |
| JardianceEmpagliflozin | 12 | $8,311 |
| Cinacalcet Hcl | 12 | $8,231 |
| Calcitriol | 292 | $6,727 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 15 | $6,081 |
| Potassium Citrate ErPotassium Citrate | 18 | $2,067 |
| Nebivolol Hcl | 28 | $1,413 |
| Colchicine | 39 | $1,254 |
| Losartan Potassium | 124 | $1,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $294,218 | $170,844213 claims |
| AstraZenecaFarxiga, Lokelma | $1,359 | $123,977129 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $120 | $20,64748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Livingston
- Shabnam GuptaLivingston$6K
- Robert SipznerLivingston$5K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
- Arif AsifNeptune$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.